Sequana Medical NV (SEQUA) - Total Liabilities

Latest as of June 2025: €53.74 Million EUR ≈ $62.83 Million USD

Based on the latest financial reports, Sequana Medical NV (SEQUA) has total liabilities worth €53.74 Million EUR (≈ $62.83 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Sequana Medical NV (SEQUA) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Sequana Medical NV - Total Liabilities Trend (2014–2024)

This chart illustrates how Sequana Medical NV's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SEQUA current and non-current assets.

Sequana Medical NV Competitors by Total Liabilities

The table below lists competitors of Sequana Medical NV ranked by their total liabilities.

Company Country Total Liabilities
FreeCast, Inc. Class A Common Stock
NASDAQ:CAST
USA $8.12 Million
SMCore.Inc
KQ:007820
Korea ₩54.09 Billion
Carlos Casado
BA:CADO
Argentina AR$18.54 Billion
Senko Co. Ltd
KQ:347000
Korea ₩14.15 Billion
Precision Optics Corporation, Inc. Common stock
NASDAQ:POCI
USA $13.58 Million
IBKS No2 SPAC
KQ:204840
Korea ₩28.80 Billion
Rothwell International Co. Limited
KQ:900260
Korea ₩657.68 Billion
Mcleod Russel India Limited
NSE:MCLEODRUSS
India Rs24.04 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down Sequana Medical NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Sequana Medical NV balance sheet quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.20 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1.37 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 3.69 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sequana Medical NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sequana Medical NV (2014–2024)

The table below shows the annual total liabilities of Sequana Medical NV from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 €54.32 Million
≈ $63.51 Million
+83.73%
2023-12-31 €29.57 Million
≈ $34.57 Million
+4.92%
2022-12-31 €28.18 Million
≈ $32.94 Million
+81.89%
2021-12-31 €15.49 Million
≈ $18.11 Million
+9.87%
2020-12-31 €14.10 Million
≈ $16.49 Million
+67.38%
2019-12-31 €8.42 Million
≈ $9.85 Million
-61.88%
2018-12-31 €22.10 Million
≈ $25.84 Million
+171.85%
2017-12-31 €8.13 Million
≈ $9.50 Million
-22.39%
2016-12-31 €10.48 Million
≈ $12.25 Million
+110.92%
2015-12-31 €4.97 Million
≈ $5.81 Million
+55.52%
2014-12-31 €3.19 Million
≈ $3.73 Million
--

About Sequana Medical NV

BR:SEQUA Belgium Medical Devices
Market Cap
$55.84 Million
€47.76 Million EUR
Market Cap Rank
#22158 Global
#93 in Belgium
Share Price
€0.61
Change (1 day)
+0.00%
52-Week Range
€0.47 - €0.97
All Time High
€11.80
About

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid over… Read more